Bortezomib is a cell-permeable dipeptidylboronate compound that acts as a potent and selective 26S proteasome inhibitor. Human pancreatic cancer cell studies demonstrate Bortezomib to inhibit the PKR-like endoplasmic reticulum (ER) kinase and enhance ER stress, leading to apoptosis.